Global pharma packaging firm Schott unveiled plans to double the capacity at its syringe competence center in Switzerland following significant facility investments. At the St. Gallen site, which has already seen a capacity increase in recent years, additional production began in June. Further capacity is being installed and will be in operation next year. The development meets the growing demand for applications that drive the market for pre-filled polymer syringes.

“Polymer syringes have a number of advantages for certain applications,” said Tom Van Ginneken, product manager, Schott. “The material maintains glass-like transparency and is resistant to breakage. The barrier properties of the Schott TopPac syringe system in particular keep the medication stable throughout its shelf life. In addition, injection molding allows for higher customization options and tighter product tolerances. These advantages support the market growth in applications such as highly viscous drugs, emergency drugs and intensive care.”

The new production capacity will integrate into Schott’s existing setup. In this facility design, Schott TopPac syringes are manufactured in clean rooms with a fully automated process starting from injection molding to the final packaging in nest and tub. Afterwards, the syringes are sterilized and ready for aseptic filling operations.